Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 5/20 | 0.69 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 12/20 | 1.00 |
| ▸ | KLK1 | P06870 | 4/20 | 1.00 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.86 |
| ▸ | ACR | P10323 | 7/20 | 0.73 |
| ▸ | TMPRSS15 | P98073 | 4/20 | 0.73 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.65 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.65 |
| ▸ | HGFAC | Q04756 | 3/20 | 0.64 |
| ▸ | PLG | P00747 | 1/20 | 0.60 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.60 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.60 |
| ▸ | HPN | P05981 | 1/20 | 0.60 |
| ▸ | CTSL | P07711 | 1/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.60 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camostat SCHEMBL29376746 | 0.82 | PRSS1 (1.00) | PRSS1KLK1TMPRSS2ACRTMPRSS15 | |
| SCHEMBL11417275 | 0.80 | PRSS1 (0.67) | PRSS1KLK1TMPRSS2ACRTMPRSS15 | |
| SCHEMBL20008707 | 0.78 | PRSS1 (0.71) | PRSS1KLK1TMPRSS2ACRTMPRSS15 | |
| SCHEMBL28467251 | 0.76 | PRSS1 (0.61) | PRSS1KLK1TMPRSS2ACRTMPRSS15 | |
| SCHEMBL20008700 | 0.76 | PRSS1 (0.88) | PRSS1KLK1TMPRSS2ACRTMPRSS15 | |
| SCHEMBL20008706 | 0.76 | PRSS1 (1.00) | PRSS1KLK1TMPRSS2ACRTMPRSS15 | |
| SCHEMBL30627528 | 0.76 | PLG (1.00) | PRSS1ACRTMPRSS15F2PRSS2 | |
| Nafamostat SCHEMBL25197320 | 0.75 | FTO (1.00) | PRSS1KLK1TMPRSS2ACRTMPRSS15 | |
| Nafamostat SCHEMBL1650158 | 0.75 | FTO (1.00) | PRSS1KLK1TMPRSS2ACRTMPRSS15 | |
| SCHEMBL4752931 | 0.75 | PRSS1 (0.61) | PRSS1KLK1TMPRSS2TMPRSS15F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569456-B2 | Methods for the treatment of cysteamine sensitive disorders | THIOGENESIS THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4534527-A2 | METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | Thiogenesis Therapeutics, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-3684418-B1 | COMPOUNDS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | THIOGENESIS THERAPEUTICS INC (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-118924717-A | Methods for treating cysteamine-sensitive disorders | 硫创治疗公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-111683684-B | Methods for treating cysteamine-sensitive disorders | 硫创治疗公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117599029-A | Compositions for controlled release of cysteamine and systematic treatment of cysteamine-sensitive disorders | 硫创治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| US-11786491-B2 | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders | THIOGENESIS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230218571-A1 | CYSTEAMINE PRECURSOR COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | THIOGENESIS THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230190683-A1 | METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | THIOGENESIS THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| CN-115884764-A | Cysteamine precursor compounds for treating coronavirus b infection | 硫创治疗公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11612576-B2 | Methods for the treatment of cysteamine sensitive disorders | THIOGENESIS THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| EP-4125839-A1 | CYSTEAMINE PRECURSOR COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | Thiogenesis Therapeutics, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20220040127-A1 | COMPOSITIONS FOR CONTROLLED RELEASE OF CYSTEAMINE AND SYSTEMIC TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | THIOGENESIS THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569456-B2 | Methods for the treatment of cysteamine sensitive disorders | SLC7A11, CTH, SLC19A1 | F2 643/4885ADRA1A 1789/4885PRSS1 888/4885 |
| US-20230218571-A1 | CYSTEAMINE PRECURSOR COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | CBS, CTH, BHMT | F2 1380/4885ADRA1A 1327/4885PRSS1 67/4885 |
| US-11612576-B2 | Methods for the treatment of cysteamine sensitive disorders | CTH, CBS, SLC19A1 | F2 406/4885ADRA1A 2367/4885PRSS1 547/4885 |
| US-20230190683-A1 | METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | CTH, CBS, SLC19A1 | F2 406/4885ADRA1A 2367/4885PRSS1 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.